DE60319083D1 - Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug - Google Patents

Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug

Info

Publication number
DE60319083D1
DE60319083D1 DE60319083T DE60319083T DE60319083D1 DE 60319083 D1 DE60319083 D1 DE 60319083D1 DE 60319083 T DE60319083 T DE 60319083T DE 60319083 T DE60319083 T DE 60319083T DE 60319083 D1 DE60319083 D1 DE 60319083D1
Authority
DE
Germany
Prior art keywords
treatment
methods
pharmaceutical compound
human carcinoma
arginine detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60319083T
Other languages
English (en)
Other versions
DE60319083T2 (de
Inventor
Ning Man Cheng
Yun Chung Leung
Wai Hung Lo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Cancer Treatment Int Ltd
Bio Cancer Treatment International Ltd
Original Assignee
Bio Cancer Treatment Int Ltd
Bio Cancer Treatment International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30000613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60319083(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bio Cancer Treatment Int Ltd, Bio Cancer Treatment International Ltd filed Critical Bio Cancer Treatment Int Ltd
Priority claimed from PCT/GB2003/002665 external-priority patent/WO2004000349A1/en
Application granted granted Critical
Publication of DE60319083D1 publication Critical patent/DE60319083D1/de
Publication of DE60319083T2 publication Critical patent/DE60319083T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60319083T 2002-06-20 2003-06-20 Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin-entzug Expired - Lifetime DE60319083T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39075702P 2002-06-20 2002-06-20
US390757P 2002-06-20
PCT/CN2002/000635 WO2004001048A1 (en) 2002-06-20 2002-09-09 Pharmaceutical composition and method of treatment of human malignancies with arginine deprivation
WOPCT/CN02/00635 2002-09-09
PCT/GB2003/002665 WO2004000349A1 (en) 2002-06-20 2003-06-20 Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation

Publications (2)

Publication Number Publication Date
DE60319083D1 true DE60319083D1 (de) 2008-03-27
DE60319083T2 DE60319083T2 (de) 2009-02-05

Family

ID=30000613

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60319083T Expired - Lifetime DE60319083T2 (de) 2002-06-20 2003-06-20 Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin-entzug
DE60331871T Expired - Lifetime DE60331871D1 (de) 2002-06-20 2003-06-20 Pharmazeutische Verbindung und Methoden zur Behandlungen von menschliche Karzinome mittels Arginin Entzug

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60331871T Expired - Lifetime DE60331871D1 (de) 2002-06-20 2003-06-20 Pharmazeutische Verbindung und Methoden zur Behandlungen von menschliche Karzinome mittels Arginin Entzug

Country Status (12)

Country Link
US (4) US7951366B2 (de)
EP (1) EP1517699B1 (de)
JP (2) JP5307042B2 (de)
CN (2) CN101433714A (de)
AT (2) ATE385807T1 (de)
AU (1) AU2002325782A1 (de)
DE (2) DE60319083T2 (de)
HK (3) HK1053577A2 (de)
IL (1) IL165858A (de)
MX (1) MXPA04012970A (de)
NZ (1) NZ537774A (de)
WO (1) WO2004001048A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745847A (zh) * 2004-09-08 2006-03-15 康达医药科技有限公司 用精氨酸酶治疗肝炎的药物组合物和方法
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
AU2007228435A1 (en) * 2006-03-17 2007-09-27 Bio-Cancer Treatment International Limited Method and composition for protection against radiation
US20080138858A1 (en) * 2006-12-12 2008-06-12 Bio-Cancer Treatment International Ltd. Expression System for Recombinant Human Arginase I
WO2010023195A2 (en) * 2008-08-26 2010-03-04 Kyon Biotech Ag Compositions and methods for treating cancer
DK2350273T3 (en) 2008-10-31 2016-06-13 Aerase Inc Compositions of engineered human arginases and methods for the treatment of cancer
WO2010124547A1 (en) * 2009-03-26 2010-11-04 The Hong Kong Polytechnic University Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
JP2012531893A (ja) * 2009-06-29 2012-12-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム アルギナーゼ製剤および方法
CN103184208B (zh) * 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和定点聚乙二醇化人精氨酸酶及其应用
EP4005590A1 (de) 2014-04-29 2022-06-01 Bio-Cancer Treatment International Ltd. Verfahren und zusammensetzungen zur modulierung des immunsystems mit arginase i
JP2016117702A (ja) * 2014-12-22 2016-06-30 武輝 山田 ガン細胞の死滅法
CN105062941B (zh) * 2015-08-25 2019-03-05 江南大学 一种利用重组枯草芽孢杆菌全细胞转化生产l-鸟氨酸的方法
US20180271960A1 (en) * 2015-09-21 2018-09-27 Bio-Cancer Treatment International Ltd. Method to treat cancer using arginine delpetor and ornithine decarboxylase (odc) inhibitor
CN105112391B (zh) * 2015-09-22 2018-07-06 浙江道尔生物科技有限公司 一种人源精氨酸酶突变体及其制备方法和用途
BR112019002458A2 (pt) 2016-08-08 2019-05-14 Aerase, Inc. composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
CA3084801A1 (en) 2017-12-05 2019-06-13 Aerase, Inc. Method and composition for treating arginase 1 deficiency
BR112020024227A2 (pt) * 2018-05-31 2021-03-16 The Hong Kong Polytechnic University Composição e aplicação de agentes depletores de arginina para câncer, obesidade, distúrbios metabólicos e complicações e comorbidades relacionadas
WO2021110071A1 (en) * 2019-12-02 2021-06-10 The Hong Kong Polytechnic University Methods for inducing intermittent fasting and modulating autophagy
CN115804845A (zh) * 2022-12-02 2023-03-17 华东理工大学 精氨酸剥夺在延缓衰老与联合化疗药物治疗肿瘤中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780286A (en) * 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
US5851985A (en) * 1996-08-16 1998-12-22 Tepic; Slobodan Treatment of tumors by arginine deprivation
EP0956864A1 (de) 1996-12-03 1999-11-17 Kyowa Hakko Kogyo Co., Ltd. Inhibitor der gewebefibrose
WO1999043345A1 (en) 1998-02-26 1999-09-02 Eisai Co., Ltd. Amino acid degrading enzymes modulate cell death
US6413757B1 (en) * 2000-02-28 2002-07-02 Millennium Pharmaceuticals, Inc. 25312, a novel human agmatinase-like homolog
CN1324945A (zh) * 2000-05-19 2001-12-05 上海博德基因开发有限公司 一种新的多肽——精氨酸酶12和编码这种多肽的多核苷酸
CN1324942A (zh) * 2000-05-19 2001-12-05 上海博德基因开发有限公司 一种新的多肽——人精氨酸酶9和编码这种多肽的多核苷酸
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
DE10047204A1 (de) 2000-09-23 2002-04-25 Henkel Kgaa Topische Hautbehandlungsmittel mit Arginase
CN1345966A (zh) * 2000-09-26 2002-04-24 上海博德基因开发有限公司 一种新的多肽——人精氨酸酶35.42和编码这种多肽的多核苷酸
CN1345970A (zh) * 2000-09-29 2002-04-24 上海博德基因开发有限公司 一种新的多肽——含精氨酸酶结构域的蛋白质9.35和编码这种多肽的多核苷酸
CA2430077A1 (en) 2000-11-28 2002-06-06 Phoenix Pharmacologics, Inc. Modified arginine deiminase
EP1499342A2 (de) 2002-01-25 2005-01-26 Cancer Treatments International Therapeutische zusammensetzung zur behandlung von krebs durch arginin-depletion

Also Published As

Publication number Publication date
US20080226617A1 (en) 2008-09-18
IL165858A (en) 2010-12-30
CN1918298B (zh) 2011-06-29
AU2002325782A1 (en) 2004-01-06
US20050244398A1 (en) 2005-11-03
MXPA04012970A (es) 2005-08-18
EP1517699A1 (de) 2005-03-30
DE60319083T2 (de) 2009-02-05
US20080248018A1 (en) 2008-10-09
ATE461707T1 (de) 2010-04-15
HK1071687A1 (en) 2005-07-29
US20090123450A1 (en) 2009-05-14
JP2013172743A (ja) 2013-09-05
NZ537774A (en) 2007-01-26
JP5307042B2 (ja) 2013-10-02
CN1918298A (zh) 2007-02-21
IL165858A0 (en) 2006-01-15
US7951366B2 (en) 2011-05-31
DE60331871D1 (de) 2010-05-06
WO2004001048A1 (en) 2003-12-31
HK1053577A2 (en) 2003-10-10
ATE385807T1 (de) 2008-03-15
US8679810B2 (en) 2014-03-25
HK1109876A1 (en) 2008-06-27
JP2010148509A (ja) 2010-07-08
CN101433714A (zh) 2009-05-20
EP1517699B1 (de) 2008-02-13

Similar Documents

Publication Publication Date Title
DE60319083D1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE463492T1 (de) Kondensierte indole als dipeptidyl-peptidase- hemmer zur behandlung oder prävention von diabetes
ATE350374T1 (de) Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
DE60330485D1 (de) Zur behandlung von diabetes
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA200100992A1 (ru) Ингибиторы фермента impdh
CY1108146T1 (el) ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ β-ΑΜΙΝΟ-ΕΤΕΡΟΚΥΚΛΙΚΗΣ-ΔΙΠΕΠΤΙΔΥΛΙΚΗΣ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗΝ ΑΓΩΓΗ Ή ΠΡΟΛΗΨΗ ΤΟΥ ΔΙΑΒΗΤΗ
DE69427127D1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
ATE517638T1 (de) Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
CY1116164T1 (el) Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
EA200500782A1 (ru) Лечение геморрагического шока
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
DE112004000961D2 (de) Verwendung von Wirksubstanzen zur Vorbeugung oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
MXPA05013226A (es) Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas.
SE0402507D0 (sv) Medicinsk lösning, förfarande för framställning och användning därav
HUP0103660A2 (hu) Mikróbaeredetű hialuronsavbontó enzimet tartalmazó gyógyászati készítmény

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: CHENG, NING MAN, HONG KONG, CN

Inventor name: LEUNG, YUN CHUNG, HUNG HOM, HONG KONG, CN

Inventor name: LO, WAI HUNG, MA ON SHAN, N.T., HONG KONG, CN

8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1517699

Country of ref document: EP

Representative=s name: CABINET CHAILLOT, 92703 COLOMBES CEDEX, FR